Newer breast cancer drug seen safer than tamoxifen

	Tweet

As add-on therapy for early-stage breast cancer, the drug anastrozole, known by the brand name Arimidex, is less likely than tamoxifen to cause adverse effects, including serious events and those leading to treatment discontinuation, new research suggests.

In 2005, the results of the “Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial were published and showed a benefit for Arimidex over tamoxifen in terms of disease-free survival,” Dr. Joan Houghton, from University College London, told Reuters Health. “With the current analysis, we just wanted to make sure Arimidex was as safe as tamoxifen.”

Arimidex does increase the risk of bone fractures, which Houghton said was anticipated, but the risk does not extend beyond the treatment phase and is easily managed. However, the newer agent has a better safety profile than tamoxifen.

The current ATAC analysis, which appears in the medical journal Lancet Oncology, includes follow-up data for 3125 women who completed 5 years of treatment with anastrozole and 3116 similar women treated with tamoxifen. The average follow-up period was 68 months.

The overall rate of side effects was significantly lower with anastrozole than with tamoxifen: 61 percent vs. 68 percent. Serious side effects were nearly half as common with anastrozole: 5 percent vs. 9 percent.

Eleven percent of anastrozole-treated patients experienced side effects leading to treatment discontinuation compared with 14 percent of tamoxifen-treated patients.

Tamoxifen has received much praise since it first became available in the 1970s, but, Houghton said, the newer types of drugs such as anastrozole “have really knocked tamoxifen off its perch.”

The study was funded by AstraZeneca, which developed both Arimidex and tamoxifen (Nolvadex), although the latter agent has been available in a generic form for several years.

SOURCE: Lancet Oncology, August 2006.

RELATED STORIES:
Overweight and obese women at greater risk of breast cancer recurrence   Smoking increased risk of death in women with breast cancer   A New Way to Study How Breast Cancer Spreads   Cough medicine could help doctors identify how breast cancer patients metabolize tamoxifen   Chicago team uses artificial intelligence to diagnose metastatic cancer   Decrease in breast cancer rates related to reduction in use of hormone replacement therapy   Breast cancer radiotherapy gentler on the heart   Linchpin Gene May Be Useful Target For Breast Cancer Therapies   Breast cancer study aims to speed drugs, cooperation   Women with personal history of breast cancer should be screened with MRI   University of Arkansas to Host National Breast Cancer Workshop   Breast cancer screening with MRI benefits women with radiation therapy history   Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads   Breast Brachytherapy Use Outpaces Evidence   Bitter melon extract attacks breast cancer cells   A novel therapeutic target to slow breast cancer cell motility   Targeted Immunotherapy: Metastatic Breast, Pancreatic Cancers   A genetic ‘gang of 4’ drives spread of breast cancer   One-step Breast Cancer Treatment Combines Radiation, Surgery   Understanding individual genetic variation can help predict chemotherapy side effects   Women Treated for Breast Cancer While Pregnant Have Improved Survival   Diabetes drug shows promise in reducing risk of cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]